Evidence method
Level · gp.fundamentals.debt_to_revenue
108.43% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
LXRX · Dec 31, 2025
LEXICON PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001062822-26-000050General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-136.24% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
729.91% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
0.56% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
99.45% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-98.21% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
122.73% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
25.13% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History10 statesHistory building
Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20240/7 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20250/7 normalizedLevel 3Sep 30, 20250/8 normalizedLevel 3Dec 31, 20250/9 normalizedLevel 3Mar 31, 20266/8 normalizedLevel 3Jun 30, 20266/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- -168.05%
- Current
- -136.24%
- Delta
- 31.81%
- Previous
- 714.59%
- Current
- 729.91%
- Delta
- 15.32%
- Previous
- 1.11%
- Current
- 0.56%
- Delta
- -0.55%
- Previous
- 99.93%
- Current
- 99.45%
- Delta
- -0.48%
- Previous
- -85.93%
- Current
- -98.21%
- Delta
- -12.28%
- Previous
- 132.26%
- Current
- 122.73%
- Delta
- -9.53%
- Previous
- 23.97%
- Current
- 25.13%
- Delta
- 1.16%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · LXRX Fundamental State →Has State · LEXICON PHARMACEUTICALS, INC. →Transitioned To · LXRX Fundamental State →Transitioned To · LXRX CASH_GENERATION_INCREASED →Transitioned To · LXRX GROWTH_INCREASED →Transitioned To · LXRX INVENTORY_PRESSURE_DECREASED →Transitioned To · LXRX MARGIN_DECREASED →Transitioned To · LXRX PROFITABILITY_DECREASED →Transitioned To · LXRX R_AND_D_INTENSITY_DECREASED →Transitioned To · LXRX SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.